Lobe Sciences Ltd
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Frederick D. Sancilio
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1771 Robson Street Vancouver BC Canada V6G 3B7
- IPO Date
- Jun 19, 2012
- Website
- lobesciences.com
- Similar Companies
- Business
- Lobe Sciences Ltd. (CSE:LOBE) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for orphan and rare diseases, including chronic cluster headache and sickle cell disease. The company advances a pipeline of proprietary compounds and medical foods, such as Conjugated Psilocin (CP), a patented non-hallucinogenic new chemical entity (NCE) for chronic cluster headache via its majority-owned subsidiary Cynaptec Pharmaceuticals Inc.; L-130 for chronic cluster headache and L-131 for pediatric anxiety; Altemia, a medical food for dietary management of sickle cell disease in adult and pediatric patients addressing inborn metabolism errors; and S-100, another treatment candidate for sickle cell disease. Lobe Sciences Ltd., founded in 2018 and headquartered in Vancouver, British Columbia, Canada, conducts research and development primarily in North America with global commercialization ambitions for its products targeting unmet needs in neurological and metabolic disorders. Recent developments include the creation of Cynaptec Pharmaceuticals Inc. as a stand-alone Delaware entity in April 2025, with Lobe owning 64% and transferring Conjugated Psilocin assets; appointment of Yong Yao as Chief Financial Officer in June 2025 and Dr. Herman Williams as CEO of Altemia Inc. in March 2025; a US$6 million private placement in April 2025 to fund pre-clinical, Phase 1, and Phase 2a studies for Conjugated Psilocin with a US$20 million Phase 3 option; notice of allowance for a second U.S. patent on Conjugated Psilocin in November 2024; engagement of Enclave Capital and Peak Asset Management in October 2025 to fund clinical trials; and a $500,000 convertible note financing with Clearway Global LLC and Quality Chemical Laboratories Inc. in June 2024 to strengthen the balance sheet ahead of larger funding rounds.
Company News
Lobe Sciences Appoints Tracy L. Goeken, M.D.
Lobe Sciences Appoints Annette Grimaldi, Former Head of Life Sciences Investment Banking at BMO Capital Markets, to Board of Directors
Lobe Sciences Announces Proposed Capital Markets Initiatives to Support Planned Growth
Lobe Sciences to Present Low-Dose L-130 Clinical Data at 9th Neuropsychiatric Drug Development Summit
Lobe Sciences to Attend the ArcStone-Kingswood Growth Summit 2026 in Toronto
Lobe Sciences Ltd. Announces Closing of Upsize to Non-Brokered Private Placement
Lobe Sciences Ltd. Announces Upsize to Non-Brokered Private Placement
Lobe Sciences Expands Leadership Team with New CFO Appointment
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement
Lobe Sciences Reports Third Quarter 2026 Financial Results
Lobe Sciences Ltd. Announces Non-Brokered Private Placement
Lobe Sciences Announces Results of Annual General and Special Meeting of Shareholders
Lobe Sciences Files Management Information Circular for Annual General and Special Meeting on July 30, 2026
Lobe Sciences Directors and Management Increase Equity Ownership Through Settlement of Accrued Fees by the Issuance of Common Shares
Lobe Sciences Announces Proposed Shares for Debt Transaction
Lobe Sciences Ltd. Announces Participation in the D.
Lobe Sciences Reports Second Quarter 2026 Results and Highlights Continued Operational Progress
Lobe Sciences Ltd. Comments on White House Executive Order Supporting Drug Development for Neurological and Mental Health Disorders
Lobe Sciences Ltd. Engages Massive Intelligence Pty Ltd for Investor Relations and Corporate Communications Services
Lobe Sciences Ltd. Announces Closing of Non-Brokered Private Placement and Provides Corporate Update